@INmuneBio

INmune Bio (Nasdaq: INMB) is developing therapies that harness patient’s immune system to treat disease. Our focus is on #cancer, #Alzheimer’s disease.

 Boca Raton, FL
inmunebio.com
Joined October 2016
  • Tweets1.7K
  • Following4.9K
  • Followers4.9K
875Media
$INMB announced FDA alignment on an integrated Phase 2b/3 registration pathway for #XPro1595 in early #alzheimers. The FDA raised no objection to the development strategy and confirmed CDR-SB as the sole primary endpoint. Full PR: bit.ly/3MG165k #RegulatoryMilestone
2
9
1,149
As #RareDiseaseMonth comes to a close, #INmuneBio recognizes the millions affected by #raredisease and the ongoing need for innovation. $INMB is advancing novel therapies for high unmet need conditions like #RDEB, a rare genetic disease with systemic impact beyond the skin.
Graphic recognizing Rare Disease Month in February, featuring overlapping human silhouettes, a white awareness ribbon, and the INmune Bio logo, representing rare genetic diseases, RDEB, and biotech research.

ALT Graphic recognizing Rare Disease Month in February, featuring overlapping human silhouettes, a white awareness ribbon, and the INmune Bio logo, representing rare genetic diseases, RDEB, and biotech research.

1
6
688
On the @Xtalks Life Science Podcast, $INMB CEO David Moss discusses #INmuneBio’s dominant-negative inhibitor platform targeting chronic inflammation. From #RDEB to #Alzheimers, learn how innate immunity may reshape treatment. Listen on @YouTube: bit.ly/4aqNHWR
2
4
735
February 14-21 is Alzheimer’s & Dementia Care Education Week, highlighting the role of education and innovation in care for those impacted by #Alzheimers. With support from the @alzassociation, $INMB is advancing therapies targeting the underlying drivers of Alzheimer’s disease.
Graphic highlighting Alzheimer’s & Dementia Care Education Week, February 14-21, featuring a purple brain illustration, blue headline text, and the INmune Bio logo in the bottom corner.

ALT Graphic highlighting Alzheimer’s & Dementia Care Education Week, February 14-21, featuring a purple brain illustration, blue headline text, and the INmune Bio logo in the bottom corner.

1
6
695
$INMB CEO & Co-Founder David Moss discusses INmune Bio’s precision immune modulation approach in Drug Discovery Online, highlighting the #CORDStrom and #XPro programs targeting harmful inflammation across rare and neurodegenerative diseases. Read more: bit.ly/4rCt7K2

Rethinking Disease Modification Through Targeted Immunotherapy

As understanding of immune-driven disease deepens, therapies that selectively correct dysregulated inflammation have the potential to reshape treatment paradigms.

drugdiscoveryonline.com
1
8
836
#INmuneBio advances #CORDStrom for #RDEB with a key regulatory milestone. $INMB has submitted its pre-submission package to the UK MHRA to streamline approval and shorten time-to-market. Full PR: bit.ly/4aq1b5d #RareDisease #RegulatoryMilestone #INMB
2
8
767
#WorldCancerDay underscores the need for smarter, more precise approaches to disease. #INmuneBio studies the innate immune system and how restoring immune balance may support new approaches to #cancer and other serious diseases. $INMB #CancerResearch #Biotech
World Cancer Day awareness graphic for INmune Bio featuring a blue background with a light-colored world map and a large blue cancer awareness ribbon centered over the map. Text at the bottom reads “World Cancer Day, Wednesday, 4 February,” with the INmune Bio Innate Immunity logo in the upper right corner.

ALT World Cancer Day awareness graphic for INmune Bio featuring a blue background with a light-colored world map and a large blue cancer awareness ribbon centered over the map. Text at the bottom reads “World Cancer Day, Wednesday, 4 February,” with the INmune Bio Innate Immunity logo in the upper right corner.

8
245
Recessive Dystrophic Epidermolysis Bullosa (#RDEB) is a rare genetic condition causing fragile skin, blisters, & challenges with eating, swallowing, joints, hair, & more. $INMB is advancing research to improve the lives of those affected. Learn more: bit.ly/47aLA7I
Awareness graphic for INmune Bio highlighting Recessive Dystrophic Epidermolysis Bullosa (RDEB). The graphic displays the condition name prominently along with a section titled “Main Symptoms,” listing skin blisters and scarring, swallowing difficulties, and joint and hair problems. The INmune Bio Innate Immunity logo appears at the top, with a grayscale image of a child’s hand being gently held by an adult on the right side.

ALT Awareness graphic for INmune Bio highlighting Recessive Dystrophic Epidermolysis Bullosa (RDEB). The graphic displays the condition name prominently along with a section titled “Main Symptoms,” listing skin blisters and scarring, swallowing difficulties, and joint and hair problems. The INmune Bio Innate Immunity logo appears at the top, with a grayscale image of a child’s hand being gently held by an adult on the right side.

7
506
Today we’re spotlighting Mark Lowdell, CSO & CMO of #INmuneBio. Serving in this role since 2015, Mark brings decades of leadership in translational #immunotherapy and cell-based medicine. Learn more: bit.ly/4mRR9hk $INMB #EmployeeSpotlight
6
482
#INmuneBio issued a shareholder letter reviewing 2025 milestones & outlining 2026 strategic initiatives, highlighting progress with #XPro1595 in early #Alzheimers disease & continued advancement of #CORDStrom in #RDEB. Read more: bit.ly/4bitRPD $INMB #ShareholderUpdate
7
302
In a recent Rare Connection podcast, Mark Lowdell, CSO & Co-Founder of $INMB, discusses #CORDStrom, an investigational cell therapy for #RDEB. The conversation highlights clinical progress, the regulatory path ahead, & patient impact. Listen on @Spotify: bit.ly/4qkdma8

New Drug for RDEB Skin Condition With Professor Mark Lowdell From The UK

Rare Connection · Episode

open.spotify.com
6
405
CEO David Moss shares his perspective on the #pharma advances that have shaped the industry over the past 30 years in a @pharmasalmanac roundtable, from biologics to advanced antibody engineering. Full roundtable featuring industry leaders: bit.ly/3LnQzen $INMB
7
507
Spotlighting Cory Ellspermann, Interim CFO at #INmuneBio. With nearly 30 years of financial leadership, Cory has been instrumental in strengthening $INMB's financial operations since joining in 2019. Proud to highlight his #leadership. Learn more: bit.ly/4mRR9hk
6
515
In a new expert discussion from @ClinicalLeader1, researchers call for a shift beyond legacy clinical trial design. David Moss, CEO and co-founder of $INMB, shares why #biology-driven endpoints and enrolling the right patients matter. Full POV: bit.ly/3YvyqhT
8
517
$INMB is advancing therapies for RDEB, a #raredisease affecting skin, causing pain, wounds, & systemic issues. Groups like @debraOfAmerica & @EBResearch support the #RDEB community, working toward better treatments and brighter futures. Learn more: bit.ly/4q2oM2Q
7
666
#INmune's CEO, David Moss, joins industry leaders in @pharmasalmanac's roundtable on how capital constraints are reshaping M&A and partnerships across pharma and CDMOs. Read the full roundtable: bit.ly/4aI2spW #INMB #PharmaTrends #Biotech
6
302
$INMB CEO David Moss spoke with @timsandle of @digitaljournal on late-stage programs targeting immune dysfunction & chronic inflammation. He shares updates on CORDStrom for #epidermolysisbullosa, XPro for #Alzheimers, and upcoming milestones. Read more: bit.ly/4b3b4Ya

Q&A: Driving biotech forward, a CEO’s view

XPro is being developed primarily for Alzheimer’s disease and mild cognitive impairment. It is a next-generation anti-TNF biologic.

digitaljournal.com
1
1
7
857
Happy Holidays from #INmuneBio! Wishing you a joyful season and a healthy, successful year ahead. #INMB #HappyHolidays
7
387
Featuring Tara Lehner, Vice President of Clinical Operations at #INmuneBio. Tara has 22+ years of experience across pharma, biotech, and CROs, and previously managed a $400 million strategic partnership portfolio. Learn more about the $IMNB team: bit.ly/4mRR9hk
8
260
#INmuneBio highlights #XPro & its potential to transform care for those affected by #Alzheimers. Hear from $INMB's CEO on the progress following the Phase 2 trial& next steps in a recent #NanoCapPodcast. Full episode: bit.ly/4o3sckk
8
362
Load more